CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome.

PURPOSE: To report the authors' experience using infliximab to treat 2 patients with Vogt-Koyanagi-Harada disease (VKH).

DESIGN: Interventional case series.

METHODS: Medical records of the 2 patients were reviewed.

RESULTS: After starting infliximab intravenous infusions, 5 mg/kg, both patients experienced rapid improvement in their VKH disease, and were able to taper and discontinue prednisone without disease recurrence for the several-month follow-up period.

CONCLUSIONS: Infliximab may be effective treatment for VKH, and spares patients the side effects of corticosteroids and conventional immunosuppressive drugs.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app